SAVA240726C14000
- 0.09
- -0.16-64.00%
Cassava Sciences Newsroom
Cassava Sciences Analyst Ratings
H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)
Cassava Sciences Analyst Ratings
Cassava Sciences (SAVA) Was Downgraded to a Hold Rating at H.C. Wainwright
Analysts Offer Insights on Healthcare Companies: Aroa Biosurgery Ltd (AU:ARX), Cassava Sciences (SAVA) and Amplifon S.p.A. (GB:0N61)
Cassava Sciences Analyst Ratings
Cassava Sciences Progresses in Phase 3 Trials, Secures Strong Cash Position: A Buy Rating Justified
Cassava Sciences Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), CymaBay Therapeutics (CBAY)
Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)
Cassava Sciences' Simufilam Efficacy and Safety in Alzheimer's Treatment Bolsters Buy Rating: An Analysis of Trial Results and Future Projections
Positive Phase 3 Trials and Undervalued Stock: Buy Rating Suggested for Cassava Sciences
Buy Rating for Cassava Sciences: Rapid Alzheimer's Trials Progress and Strong Financial Health
Cassava Sciences (SAVA) Gets a Buy From JonesTrading
HC Wainwright & Co. Reiterates Buy on Cassava Sciences, Maintains $124 Price Target
Cassava Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Stoke Therapeutics (STOK) and Cassava Sciences (SAVA)
JonesTrading Remains a Buy on Cassava Sciences (SAVA)
HC Wainwright & Co. Reiterates Buy on Cassava Sciences, Maintains $124 Price Target